oculis.com - שינוי בהכנסות משנה לשנה ב-12 החודשים האחרונים OCS

The TTM year-over-year product sales volume dynamics, where the indicator stood at 0.00, confirm the success of Oaktree Specialty Lending (OCS) in establishing ophthalmological alliances to accelerate the release of eye drops. However, stringent FDA requirements and patent protection for formulas create significant barriers to entry. Meanwhile, the company is competing with industry behemoths that are actively acquiring promising biotech startups.
oculis.com - פילוחים אנליטיים ומדדי מפתח (OCS)

For the biotechnology business of Oaktree Specialty Lending (OCS), which relies on R&D and external manufacturing outsourcing, revenue dynamics serve as a key indicator of patent commercialization. The TTM annual revenue change compares the current trailing twelve-month total with the same period last year, allowing investors to promptly assess business growth rates and avoid value traps when analyzing recent financial statements.